

RNAi Therapeutics and Technology Market (Focus on siRNA, miRNA, shRNA and DNA) (3rd Edition) by Key Therapeutic Areas (Oncological Disorders, Genetic Disorders, Metabolic Disorders, Hematological Disorders, Ophthalmic Disorders and Other Disorders), Route of Administration (Subcutaneous, Intravenous, Topical and Intradermal), Leading Industry Players, Type of RNAi Molecule (siRNA and shRNA) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2022-2035

<https://marketpublishers.com/r/R28AD13E6BD8EN.html>

Date: May 2022

Pages: 421

Price: US\$ 4,799.00 (Single User License)

ID: R28AD13E6BD8EN

Abstracts

The projected value of RNAi therapeutics and technology market is expected to be valued at USD 1,200 million in 2022 and is anticipated to grow at a CAGR of 17% during the forecast period 2022-2035.

RNA interference (RNAi) therapy has gained significant prominence following the recognition of Andrew Fire and Craig Mello with the 2006 Nobel Prize for their groundbreaking discovery of RNA interference technology. The approval of ONPATTRO® in 2018 marked a pivotal moment, propelling the RNAi therapeutics and technology market into a phase of heightened activity. Subsequently, regulatory authorities approved three more RNAi therapies: GIVLAARI® (November 2019), LEQVIO® (October 2020), and OXLUMO™ (November 2020), in a chronological sequence. Presently, an extensive clinical landscape is evolving, with over 200 RNAi therapeutics undergoing evaluation across various clinical trials, encompassing a

diverse spectrum of disease indications, including potential applications for treating COVID-19. Notwithstanding the promising attributes of RNAi therapy, developers encounter challenges pertaining to the stability and targeted delivery of their therapeutic candidates. In response to these challenges, several companies have pioneered the development of novel RNA interference technology and delivery systems, aiming to ensure the precise delivery of these therapeutic molecules.

These innovative strides have reoriented the focus of therapy developers towards the burgeoning field of RNAi therapeutics and RNA interference technology. Initiatives are actively exploring the considerable potential of these therapeutic modalities in controlling disease-associated gene expression, thereby broadening the scope of precision medicine applications. Furthermore, the safety demonstrated in systemic delivery has expanded the horizons for RNAi therapy applications. The transformative attributes of RNAi therapeutics, characterized by high specificity, efficiency, and long-term gene silencing capabilities, have captured the attention of major pharmaceutical players. Consequently, substantial investments totaling USD 8.5 billion have been injected into the field over the last five years. This financial commitment underscores the industry's confidence in the potential of RNAi therapeutics. The research community's dedication is reflected in the prolific publication of over 3,000 articles related to RNAi therapeutics and technologies, accompanied by the filing and granting of over 2,100 patents.

With the ongoing momentum in research activities and technological advancements, the RNAi therapeutics and technology market is poised for a trajectory of steady growth during the forecast period. This trajectory is indicative of the industry's resilience and commitment to realizing the full potential of RNA interference technology in revolutionizing the biopharmaceutical landscape.

Report Coverage

A historical overview of RNAi therapeutics, detailing RNA molecules, mechanisms of action, and application areas, while highlighting key advantages and challenges.

Over 200 RNAi pipeline candidates in various development stages, considering parameters such as phase, target indication, therapeutic areas, and more.

An overview of players in RNAi therapeutics development, including establishment year, company size, and headquarters, with a logo landscape

based on these factors.

A three-dimensional bubble analysis of key players, evaluating developer and product portfolio strengths in terms of employee count, years of experience, and RNAi molecules.

Detailed profiles of advanced-stage drug candidates, covering development status, mechanisms, routes of administration, and recent clinical trial results.

The current market landscape of technology platforms for RNAi therapeutics, considering purposes, types of molecules, and targeted cells/tissues, with brief profiles of key platforms.

A technology competitiveness analysis, benchmarking RNAi technologies based on supplier power and key technology specifications.

A potential target indication in various therapeutic areas for companies engaged in RNAi therapeutics development.

An analysis of completed, ongoing, and planned clinical studies based on parameters like trial registration year, phase, RNAi molecule type, and regional distribution.

Key opinion leaders (KOLs) in the RNAi therapeutics domain, employing a 2X2 analysis based on their experience and contributions.

Insights from a detailed patent analysis, covering filed/granted patents related to RNAi therapeutics since 2016, including patent benchmarking and valuation.

Detailed review around 3,000 peer-reviewed articles on RNAi therapeutics research, considering parameters like publication year, keywords, journals, and funding.

An analyzes partnerships related to RNAi therapeutics, covering types, years, disease indications, financial details, and active players.

Detailed investments made by players in RNAi therapeutics from 2016-2021, considering funding types, amounts, RNAi molecule types, and key investors.

Estimation of the annual clinical and commercial demand for RNAi therapeutics, considering the target patient population in ongoing/planned trials.

A forecast analysis of the RNAi therapeutics market until 2035, including sales projections and detailed market segmentation.

Key Market Companies

AgelessRx

ANOVA Institute for Regenerative Medicine

Betterhumans

BioAge Labs

bioXcellerator

Cambrian Biopharma

Gero.ai

Mayo Clinic

Rejuvenate Bio

UT Health San Antonio

Contents

1. PREFACE

- 1.1. Scope of the Report
- 1.2. Research Methodology
- 1.3. Market Segmentations
- 1.4. Key Questions Answered
- 1.5. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

- 3.1. Chapter Overview
- 3.2. Key Milestones and Historical Trends
 - 3.2.1. Discovery of RNAi
 - 3.2.2. RNAi Therapy Development Efforts
- 3.3. Mechanism of RNAi
 - 3.3.1. Components of RNAi
 - 3.3.2. Cellular Mechanism
- 3.4. Types of RNAi Molecules
 - 3.4.1. siRNA
 - 3.4.2. miRNA
 - 3.4.3. shRNA
- 3.5. Applications of RNAi
 - 3.5.1 Functional Genomics
 - 3.5.2 Therapeutics
 - 3.5.3. Biotechnology
 - 3.5.4. Genome-scale Screening
- 3.6. Advantages and Disadvantages of RNAi
 - 3.6.1 Advantages of RNAi
 - 3.6.2 Disadvantages of RNAi
 - 3.6.3 Case Study: Concerns Discussed During Regulatory Submissions in Clinic
- 3.7. Future Perspectives

4. MARKET OVERVIEW

- 4.1. Chapter Overview

4.2. RNAi Therapeutics: Marketed and Development Pipeline

- 4.2.1. Analysis by Type of RNAi Molecule
- 4.2.2. Analysis by Phase of Development
- 4.2.3. Analysis by Type of Molecule and Phase of Development
- 4.2.4. Analysis by Target Gene
- 4.2.5. Analysis by Therapeutic Area
- 4.2.6. Analysis by Route of Administration
- 4.2.7. RNAi Therapeutics: Special Designations
- 4.2.8. Key Players

5. COMPETITIVE LANDSCAPE

5.1. Chapter Overview

5.2. RNAi Therapeutics: Developer Landscape

- 5.2.1. Analysis by Year of Establishment
- 5.2.2. Analysis by Company Size
- 5.2.3. Analysis by Location of Headquarters
- 5.2.4. Analysis by Location of Headquarters (Country-wise)
- 5.2.5. Key Players: Analysis by Number of Drug Candidates

5.3 RNAi Therapeutics: Regional Landscape

6. COMPANY COMPETITIVENESS ANALYSIS

6.1. Chapter Overview

6.2. Assumptions / Key Parameters

6.3. Methodology

6.4. Company Competitive Analysis: RNAi Therapeutics Developers

6.4. Developers based in North America

6.5. Developers based in Europe

6.6. Developers based in Asia-Pacific

7. APPROVED AND LATE STAGE RNAI THERAPEUTICS

7.1. Chapter Overview

7.2. Onpattro®

- 7.2.1. Drug Overview
- 7.2.2. Technology Overview
- 7.2.3. Current Development Status
- 7.2.4. Recent Clinical Trial Results

- 7.2.5. Recent Partnerships
- 7.3. Givlaari®
 - 7.3.1. Drug Overview
 - 7.3.2. Technology Overview
 - 7.3.3. Current Development Status
 - 7.3.4. Recent Clinical Trial Results
 - 7.3.5. Recent Partnerships
- 7.4. Leqvio®
 - 7.4.1. Drug Overview
 - 7.4.2. Technology Overview
 - 7.4.3. Current Development Status
 - 7.4.4. Recent Clinical Trial Results
 - 7.4.5. Recent Partnerships
- 7.5. Oxlumo™
 - 7.5.1. Drug Overview
 - 7.5.2. Technology Overview
 - 7.5.3. Current Development Status
 - 7.5.4. Recent Clinical Trial Results
 - 7.5.5. Recent Partnerships
- 7.6. Fitusiran
 - 7.6.1. Drug Overview
 - 7.6.2. Technology Overview
 - 7.6.3. Current Development Status
 - 7.6.4. Recent Clinical Trial Results
- 7.7. Vutrisiran
 - 7.7.1. Drug Overview
 - 7.7.2. Technology Overview
 - 7.7.3. Current Development Status
 - 6.7.4. Recent Clinical Trial Results
- 7.8. SYL 1001
 - 7.8.1. Drug Overview
 - 7.8.2. Technology Overview
 - 7.8.3. Current Development Status
 - 7.8.4. Recent Clinical Trial Results
- 7.9. Vigil-EWS
 - 7.9.1. Drug Overview
 - 7.9.2. Technology Overview
 - 7.9.3. Current Development Status
 - 7.9.4. Recent Clinical Trial Results

- 7.10. SR-061
 - 7.10.1. Drug Overview
 - 7.10.2. Technology Overview
 - 7.10.3. Current Development Status
- 7.11. Nedosiran
 - 7.11.1. Drug Overview
 - 7.11.2. Technology Overview
 - 7.11.3. Current Development Status
 - 7.11.4. Recent Clinical Trial Results

8. TECHNOLOGY PLATFORMS AND DELIVERY SYSTEMS

- 8.1. Chapter Overview
- 8.2. Components of RNAi Delivery Systems
 - 8.2.1. RNAi Triggers
 - 8.2.1.1. Asymmetric siRNA (cp-siRNA)
 - 8.2.1.2. DNA Directed RNAi (ddRNAi)
 - 8.2.1.3. Dicer Substrate siRNA (DsiRNA)
 - 8.2.1.4. Naked siRNA
 - 8.2.1.5. Self-Deliverable RNA (sd-RNA)
 - 8.2.1.6. Self-Deliverable rxRNA (sd-rxRNA)
 - 8.2.1.7. Unlocked Nucleobase Analog (UNA) Containing siRNA (UsiRNA)
 - 8.2.2. Technology Platforms and Delivery Systems
 - 8.2.2.1. Analysis by Purpose of Technology
 - 8.2.2.2. Analysis by Type of Molecule (s) Delivered
 - 8.2.2.3. Analysis by Type of Cell (s) / Tissue (s) Targeted
 - 8.2.3. Technology Platforms: List of Developers
 - 8.2.3.1. Analysis by Year of Establishment
 - 8.2.3.2. Analysis by Company Size
 - 8.2.3.3. Analysis by Location of Headquarters (Continent-wise)
 - 8.2.3.4. Analysis by Location of Headquarters (Country-wise)
 - 8.2.4. Technology Platform: Profiles
 - 8.2.4.1. Conjugated Delivery Technologies
 - 8.2.4.1.1. GalNAc Conjugate Delivery System, Alnylam Pharmaceuticals
 - 8.2.4.1.1.1. Technology Overview
 - 8.2.4.1.1.2 Pipeline Molecules in Development
 - 8.2.4.1.1.3 Analyst's Perspective
 - 8.2.4.1.2. Protein Nanoparticle (PNP) Delivery Technology, Ariz Precision Medicine
 - 8.2.4.1.2.1. Technology Overview

- 8.2.4.1.2.2. Pipeline Molecules in Development
- 8.2.4.1.2.3 Analyst's Perspective
- 8.2.4.2.3 Targeted RNAi Molecule (TRiM) Platform, Arrowhead Pharmaceuticals
 - 8.2.4.2.3.1. Technology Overview
 - 8.2.4.2.3.2 Pipeline Molecules in Development
 - 8.2.4.2.3.3 Analyst's Perspective
- 8.2.4.2. Drug Discovery and Development Technologies
 - 8.2.4.2.1. GalXC Conjugated RNAi Technology Platform, Dicerna Pharmaceuticals
 - 8.2.4.2.1.1. Technology Overview
 - 8.2.4.2.1.2 Pipeline Molecules in Development
 - 8.2.4.2.1.3 Analyst's Perspective
 - 8.2.4.2.2. The Vigil Platform, Gradalis
 - 8.2.4.2.2.1. Technology Overview
 - 8.2.4.2.2.2 Pipeline Molecules in Development
 - 8.2.4.2.2.3 Analyst's Perspective
 - 8.2.4.2.3. mRNAi GOLD Platform, Silence Therapeutics
 - 8.2.4.2.3.1. Technology Overview
 - 8.2.4.2.3.2 Pipeline Molecules in Development
 - 8.2.4.2.3.3 Analyst's Perspective

9. TECHNOLOGY COMPETITIVENESS ANALYSIS

- 9.1. Chapter Overview
- 9.2. Assumptions / Key Parameters
- 9.3. Methodology
- 9.4. Technology Competitiveness Analysis: RNAi Therapeutics Technologies
 - 9.4.1. Technology Competitiveness Analysis: Drug Delivery Technologies
 - 9.4.2. Technology Competitiveness Analysis: Drug Discovery / Development Technologies

10. KEY THERAPEUTIC INDICATIONS

- 10.1. Chapter Overview
- 10.2. Oncological Disorders
 - 10.2.1. Analysis by Target Indication and Phase of Development
 - 10.2.2. Analysis by Type of RNAi Molecule
- 10.3. Infectious Diseases
 - 10.3.1. Analysis by Target Indication and Phase of Development
 - 10.3.2. Analysis by Type of RNAi Molecule

10.4. Metabolic Disorders

10.4.1. Analysis by Target Indication and Phase of Development

10.4.2. Analysis by Type of RNAi Molecule

10.5. Ophthalmic Diseases

10.5.1. Analysis by Target Indication and Phase of Development

10.5.2. Analysis by Type of RNAi Molecule

10.6. Genetic Disorders

10.6.1. Analysis by Target Indication and Phase of Development

10.6.2. Analysis by Type of RNAi Molecule

11. CLINICAL TRIAL ANALYSIS

11.1. Chapter Overview

11.2. Scope and Methodology

11.3. RNAi Therapeutics: Clinical Trial Analysis

11.3.1. Analysis by Trial Registration Year

11.3.2. Analysis by Trial Phase

11.3.3. Analysis by Trial Recruitment Status

11.3.4. Analysis by Type of Sponsor / Collaborator

11.3.5. Analysis by Type of RNAi Molecule and Trial Recruitment Status

11.3.6. Analysis by Therapeutic Area

11.3.7. Geographical Analysis by Number of Clinical Trials

11.3.8. Geographical Analysis by Number of Clinical Trials, Trial Phase and Recruitment Status

11.3.9. Geographical Analysis by Number of Clinical Trials and Type of RNAi Molecule

11.3.10. Geographical Analysis by Number of Clinical Trials, Type of RNAi Molecule and Trial Phase

11.3.11. Geographical Analysis by Number of Clinical Trials and Therapeutic Area

11.3.12. Geographical Analysis by Number of Clinical Trials, Therapeutic Area and Trial Phase

11.3.13. Geographical Analysis of Enrolled Patient Population by Location of Trial

11.3.14. Geographical Analysis of Enrolled Patient Population by Trial Phase and Trial Recruitment Status

11.3.15. Geographical Analysis of Enrolled Patient Population by Type of RNAi Molecule and Location of Trial

11.3.16. Geographical Analysis of Enrolled Patient Population by Type of RNAi Molecule, Trial Phase and Location of Trial

11.3.17. Geographical Analysis of Enrolled Patient Population by Therapeutic Area and Location of Trial

11.3.18. Geographical Analysis of Enrolled Patient Population by Therapeutic Area.
Trial Phase and Location of Trial

11.4. Concluding Remarks

11.4.1. Key Therapeutic Candidates

11.4.2. Key Clinical Trials

12. KEY OPINION LEADERS

12.1. Chapter Overview

12.2. RNAi Therapeutics: Key Opinion Leaders

12.2.1. Analysis by Type of Organization

12.2.2. Analysis by Qualification

12.2.3. Analysis by Geographical Location of KOLs

12.2.4. Most Prominent Organizations: Analysis by Number of KOLs

12.2.5. KOL Activeness v/s KOL Strength

12.2.6. Most Prominent KOLs: Analysis by KOL Strength

12.2.7. Most Prominent KOLs: Comparison of RA Score and Third-Party Score

13. PATENT ANALYSIS

13.1. Chapter Overview

13.2. Scope and Methodology

13.3. RNAi Therapeutics: Patent Analysis

13.3.1. Analysis by Publication Year

13.3.2. Analysis by Patent Type and Publication Year

13.3.3. Analysis by CPC Code

13.3.4. Analysis by Type of Applicant

13.3.5. Analysis by Geography

13.3.5.1. Analysis by Geography: North American Scenario

13.3.5.2. Analysis by Geography: European Scenario

13.3.5.3. Analysis by Geography: Asia-Pacific Scenario

13.3.6. Emerging Focus Areas

13.3.7. Leading Players: Analysis by Number of Patents

13.4. RNAi Therapeutics: Patent Benchmarking Analysis

13.4.1. Analysis by Key Patent Characteristics

13.4.1.1. Arrowhead Pharmaceuticals and Sirna Therapeutics

13.4.1.2. Other Leading Patent Assignees

13.5. RNAi Therapeutics: Patent Valuation Analysis

14. PUBLICATION ANALYSIS

- 14.1. Chapter Overview
- 14.2. Scope and Methodology
- 14.3. Analysis by Year of Publication
- 14.4. Analysis by Type of Publication
- 14.5. Most Popular Keywords
- 14.6. Most Popular Journals: Analysis by Number of Publications
- 14.7. Most Popular Publisher: Analysis by Number of Publications
- 14.8. Most Popular Copyright Holders: Analysis by Number of Publications
- 14.9. Key Funding Institutes: Analysis by Number of Publications

15. PARTNERSHIPS AND COLLABORATIONS

- 15.1. Chapter Overview
- 15.2. Partnership Models
- 15.3. RNAi Therapeutics: Recent Partnerships and Collaborations
 - 15.3.1. Analysis by Year of Partnership
 - 15.3.2. Analysis by Type of Partnership
 - 15.3.3. Analysis by Type of RNAi Molecule
 - 15.3.4. Analysis by Scale of Partnership
 - 15.3.5. Analysis by Therapeutic Area
 - 15.3.6. Most Active Players: Analysis by Number of Partnerships
 - 15.3.7. Regional Analysis
 - 15.3.7.1. Country-wise Distribution
 - 15.3.7.2. Intercontinental and Intracontinental Deals

16. FUNDING AND INVESTMENT ANALYSIS

- 16.1. Chapter Overview
- 16.2. Types of Funding
- 16.3. RNAi Therapeutics: Funding and Investment Analysis
 - 16.3.1. Analysis by Cumulative Funding Instances, 2014-2021
 - 16.3.2. Analysis by Amount Invested
 - 16.3.3. Analysis by Type of Funding
 - 16.3.4. Analysis by Year and Type of Funding
 - 16.3.5. Analysis of Amount Invested Across Different Types of RNAi Molecules
 - 16.3.6. Regional Analysis by Amount Invested
 - 16.3.7. Most Active Players

- 16.3.8. Key Investors
- 16.4. Concluding Remarks

17. KEY COMMERCIALIZATION STRATEGIES

- 17.1. Chapter Overview
- 17.2. Successful Drug Launch Strategy: ROOTS Framework
- 17.3. Successful Drug Launch Strategy: Product Differentiation
- 17.4. Commonly Adopted Commercialization Strategies based on Stage of Development of the Product
- 17.5. Approved RNAi Therapeutics
- 17.6. Key Commercialization Strategies Adopted by RNAi-based Therapy Developers
 - 17.6.1. Strategies Adopted Before Therapy Approval
 - 17.6.1.1. Participation in Global Events
 - 17.6.1.1.1. Onpattro
 - 17.6.1.1.2. Givlaari
 - 17.6.1.1.3. Oxlumo
 - 17.6.1.2. Collaboration with Stakeholders and Pharmaceutical Firms
 - 17.6.1.2.1. Leqvio
 - 17.6.1.3. Indication Expansion
 - 17.6.1.3.1. Onpattro
 - 17.6.1.3.2. Givlaari
 - 17.6.1.3.3. Oxlumo
 - 17.6.1.3.4. Leqvio
 - 17.6.2. Strategies Adopted During / Post Therapy Approval
 - 17.6.2.1. Participation in Global Events
 - 17.6.2.1.1. Onpattro
 - 17.6.2.1.2. Leqvio
 - 17.6.2.2. Geographical Expansion
 - 17.6.2.2.1. Onpattro
 - 17.6.2.2.2. Givlaari
 - 17.6.2.2.3. Oxlumo
 - 17.6.2.2.4. Leqvio
 - 17.6.2.3. Patient Assistance Programs
 - 17.6.2.3.1. Onpattro
 - 17.6.2.3.2. Givlaari
 - 17.6.2.3.3. Oxlumo
 - 17.6.2.4. Awareness Through Product Websites
 - 17.6.2.5. Collaboration with Stakeholders and Pharmaceutical Firms

- 17.6.2.5.1. Onpattro
- 17.6.2.5.2. Givlaari
- 17.6.2.5.3. Oxlumo
- 17.6.2.5.4. Leqvio
- 17.6.2.6. Aligning with Government Initiatives to Ensure High Adoption Rate
 - 17.6.2.6.1. Onpattro
 - 17.6.2.6.2. Givlaari
 - 17.6.2.6.3. Leqvio
- 17.7. Concluding Remarks

18. RNAI IN DIAGNOSTICS

- 18.1. Chapter Overview
- 18.2. Key Characteristics of Biomarkers
- 18.3. Circulating miRNA Biomarkers
- 18.4. miRNA Biomarkers in Oncological Disorders
 - 18.4.1. Importance of Early Cancer Detection
 - 18.4.2. Cancer Screening and Diagnosis
 - 18.4.3. Conventional Cancer Diagnostics
 - 18.4.3.1. Biopsy
 - 18.4.4. Need for Non-Invasive Approaches
 - 18.4.5. Key Indications
 - 18.4.5.1. Breast Cancer
 - 18.4.5.2. Colorectal Cancer
 - 18.4.5.3. Gastric Cancer
 - 18.4.5.4. Hematological Cancer
 - 18.4.5.4.1. Acute Myeloid Leukemia
 - 18.4.5.4.2 Lymphoma
 - 18.4.5.5. Lung Cancer
 - 18.4.5.6. Prostate Cancer
- 18.5. miRNA Biomarkers in Cardiovascular Diseases
 - 18.5.1. Key Indications
 - 18.5.1.1. Coronary Artery Disease
 - 18.5.1.2. Myocardial Infarction
- 18.6. miRNA Based Diagnostic Tests

19. RNAI THERAPEUTICS SERVICE PROVIDERS

- 19.1. Chapter Overview

- 19.2. Analysis by Types of Service Providers
- 19.3. RNAi Therapeutics: List of CROs
 - 19.3.1. Analysis by Year of Establishment
 - 19.3.2. Analysis by Location of Headquarters
 - 19.3.3. Analysis by Company Size
 - 19.3.4. Analysis by Type of RNAi Molecule
- 19.4. RNAi Therapeutics: List of CMOs
 - 19.4.1. Analysis by Year of Establishment
 - 19.4.2. Analysis by Location of Headquarters
 - 19.4.3. Analysis by Company Size
 - 19.4.4. Analysis by Type of RNAi Molecule
- 19.5. RNAi Therapeutics: List of Consumables and Other Service Providers
 - 19.5.1. Analysis by Year of Establishment
 - 19.5.2. Analysis by Location of Headquarters
 - 19.5.3. Analysis by Company Size
 - 19.5.4. Analysis by Type of RNAi Molecule

20. DEMAND ANALYSIS

- 20.1. Chapter Overview
- 20.2. Methodology
- 20.3. Global Demand for RNAi Therapeutics, 2022-2035
 - 20.3.1. Analysis by Therapeutic Approach
 - 20.3.2. Analysis by Target Therapeutic Area
 - 20.3.3. Analysis by Route of Administration
 - 20.3.4. Analysis by Key Players
 - 20.3.5. Analysis by Geography

21. MARKET SIZING AND OPPORTUNITY ANALYSIS

- 21.1. Chapter Overview
- 21.2. Scope and Limitations
- 21.3. Key Assumptions and Forecast Methodology
- 21.4. Overall RNAi Therapeutics Market, 2022-2035
 - 21.4.1. RNAi Therapeutics Market: Analysis by Type of RNAi Molecule
 - 21.4.2. RNAi Therapeutics Market: Analysis by Therapeutic Area
 - 21.4.3. RNAi Therapeutics Market: Analysis by Route of Administration
 - 21.4.4. RNAi Therapeutics Market: Share of Leading Players
 - 21.4.5. RNAi Therapeutics Market: Analysis by Geography

- 21.5. RNAi Therapeutics Market: Value Creation Analysis
- 21.6. RNAi Therapeutics Market: Product-wise Sales Forecasts
 - 21.6.1. Onpattro®
 - 21.6.1.1. Target Patient Population
 - 21.6.1.2. Sales Forecast
 - 21.6.1.3. Net Present Value
 - 21.6.1.4. Value Creation Analysis
 - 21.6.2. Givlaari™
 - 21.6.2.1. Target Patient Population
 - 21.6.2.2. Sales Forecast
 - 21.6.2.3. Net Present Value
 - 21.6.2.4. Value Creation Analysis
 - 21.6.3. Leqvio®
 - 21.6.3.1. Target Patient Population
 - 21.6.3.2. Sales Forecast
 - 21.6.3.3. Net Present Value
 - 21.6.3.4. Value Creation Analysis
 - 21.6.4. Oxlumo™
 - 21.6.4.1. Target Patient Population
 - 21.6.4.2. Sales Forecast
 - 21.6.4.3. Net Present Value
 - 21.6.4.4. Value Creation Analysis
 - 21.6.5. Fitusiran
 - 21.6.5.1. Target Patient Population
 - 21.6.5.2. Sales Forecast
 - 21.6.5.3. Net Present Value
 - 21.6.5.4. Value Creation Analysis
 - 21.6.6. Vutrisiran
 - 21.6.6.1. Target Patient Population
 - 21.6.6.2. Sales Forecast
 - 21.6.6.3. Net Present Value
 - 21.6.6.4. Value Creation Analysis
 - 21.6.7. SYL-1001
 - 21.6.7.1. Target Patient Population
 - 21.6.7.2. Sales Forecast
 - 21.6.7.3. Net Present Value
 - 21.6.7.4. Value Creation Analysis
 - 21.6.8. Vigil-EWS
 - 21.6.8.1. Target Patient Population

- 21.6.8.2. Sales Forecast
- 21.6.8.3. Net Present Value
- 21.6.8.4. Value Creation Analysis
- 21.6.9. Nedosiran
 - 21.6.9.1. Target Patient Population
 - 21.6.9.2. Sales Forecast
 - 21.6.9.3. Net Present Value
 - 21.6.9.4. Value Creation Analysis

22. SWOT ANALYSIS

- 22.1. Chapter Overview
- 22.2. Strengths
- 22.3. Weaknesses
- 22.4. Opportunities
- 22.5. Threats
- 22.6 Comparison of SWOT Factors
 - 22.6.1 Concluding Remarks

23. INTERVIEW TRANSCRIPT(S)

24. CONCLUSION

- 24.1. Chapter Overview
- 24.2. Key Takeaways

25. APPENDIX 1: TABULATED DATA

26. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

I would like to order

Product name: RNAi Therapeutics and Technology Market (Focus on siRNA, miRNA, shRNA and DNA) (3rd Edition) by Key Therapeutic Areas (Oncological Disorders, Genetic Disorders, Metabolic Disorders, Hematological Disorders, Ophthalmic Disorders and Other Disorders), Route of Administration (Subcutaneous, Intravenous, Topical and Intradermal), Leading Industry Players, Type of RNAi Molecule (siRNA and shRNA) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2022-2035

Product link: <https://marketpublishers.com/r/R28AD13E6BD8EN.html>

Price: US\$ 4,799.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R28AD13E6BD8EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970